医学
内科学
肺癌
肿瘤科
危险系数
化疗
临床试验
化学免疫疗法
癌症
杜瓦卢马布
实体瘤疗效评价标准
免疫疗法
临床研究阶段
外科
置信区间
无容量
作者
Tafadzwa L. Chaunzwa,Jack M. Qian,Qin Li,Biagio Ricciuti,Leonard Nuernberg,Justin W. Johnson,Jakob Weiß,Zhongyi Zhang,J. Mackay,Ioannis Kagiampakis,Damián E. Bikiel,Alessandro Di Federico,Joao V. Alessi,Raymond H. Mak,Etai Jacob,Mark M. Awad,Hugo J.W.L. Aerts
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2024-05-23
卷期号:10 (6): 773-773
被引量:28
标识
DOI:10.1001/jamaoncol.2024.1120
摘要
The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI